Has Susan Lee, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,513 in general payments to Susan Lee, MD across 84 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susan Lee, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susan Lee, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susan Lee, MD

Internal Medicine · Chatham, NJNPI 1669695623

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.1% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,451 and has fallen 92.3% since, to $112 in 2025.

$2,513in general payments, 2019–2025

Across 84 payments — averaging $29.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$560
AbbVie$536
UCB, Inc.$425
GSK$221
Lilly USA, LLC$137
Johnson & Johnson$79
plus $555 from 14 others

$32,249in research payments, 2019–2025

Across 5 payments — averaging $6449.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$32K

What the payments were for

Consulting fees$1606%
Food & beverage$2,31492%
Education$392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	17	$560
AbbVie	11	$536
UCB, Inc.	11	$425
GSK	6	$221
Lilly USA, LLC	8	$137
Johnson & Johnson	3	$79
AstraZeneca	5	$78
Novartis	4	$77
Kedrion Biopharma, Inc.	2	$70
Aurinia Pharma U.S., Inc.	3	$57
Sandoz	2	$46
Lundbeck LLC	2	$38
ANI Pharmaceuticals, Inc.	1	$31
Boehringer Ingelheim	2	$31
Collegium Pharmaceutical, Inc.	2	$29
Kiniksa Pharmaceuticals, Ltd.	1	$27
Otsuka America Pharmaceutical, Inc.	1	$23
Actelion Pharmaceuticals US, Inc.	1	$16
Ferring Pharmaceuticals Inc.	1	$16
Pfizer	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,513 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey →

Medicare billing

Part B allowed, 2024

$554,530

Medicare patients

465

Services billed

56,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	47	$433,378
Enbrel SureclickEtanercept	23	$181,109
Cosentyx Sensoready PenSecukinumab	19	$147,514
Hydroxychloroquine Sulfate	429	$18,992
MethotrexateMethotrexate Sodium	463	$10,338
Leflunomide	77	$6,212
Sulfasalazine	103	$2,907
Gabapentin	155	$2,353
Duloxetine Hcl	118	$2,139
Prednisone	278	$1,746
Tramadol Hcl	167	$1,515
Pregabalin	75	$1,434
Colchicine	16	$1,004
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	37	$850
Celecoxib	37	$820

Paid to pharmacies, not to this prescriber.

Other internal medicine in Chatham

David ShulkinMorristown$1.7M
Howard UdermanLakewood$955K
Darshi SunderamEast Orange$530K
Annika DrongeEmerson$401K
Stephen MarcellaNew Brunswick$331K
Viju VijaysadanKinnelon$325K
Mark MonaneWoodcliff Lake$268K
Martin BedigianLivingston$240K
Rameck HuntPlainsboro$217K
Angel LazoSecaucus$195K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →